본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

GC Cell Held an Investigator’s Meeting for Phase III Clinical Trial for Pancreatic Cancer
2021-07-12
GC Cell Held an Investigator’s Meeting for Phase III Clinical Trial for Pancreatic Cancer
GC Cell, a company specializing in cell therapy, held an investigator’s meeting for a phase 3 clinical trial for pancreatic cancer at the Sheraton Hotel in Gangnam on the 8th of this month.
The investigator's meeting was intended to discuss the current status and major plans of the clinical trial with the principal investigators participating in the Phase III clinical trial of Immune cell LC Injection for pancreatic cancer.
Through this event, GC Cell introduced the clinical trial background and plan for the successful phase III clinical trial of Immune Cell LC Injection for pancreatic cancer, and the principal investigators participating from the multi-centers had a time to discuss the purpose, procedures, and details of clinical trial together and to share information with each other.
Meanwhile, GC Cell received the approval of the Immune Cell LC Injection Phase III clinical trial plan for pancreatic cancer from the Ministry of Food and Drug Safety in December 2020. It is planning to conduct clinical trials in earnest by recruiting patients from clinical institutions such as Seoul National University Hospital.
As a sponsor of this Phase III clinical trial, GC Cell will do its best to conduct clinical trials smoothly through responsible support and will focus on company-wide capabilities to successfully expand the therapeutic options for pancreatic cancer treatment, which is in high demand.
Next
GC Cell Completes pct for entry into the global market
Previous
GC Cell Accelerates the Expansion of CDMO Business!